Mindset Pharma says new study data indicates MSP-1014 is safer and more effective than generic psilocybin in treating neuropsychiatric disorders

Mindset Pharma Inc (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) revealed positive new study data on its psychedelic compound MSP-1014.

The drug discovery company said MSP-1014 demonstrated “superior efficacy” and an improved safety profile compared to generic psilocybin in a head-to-head clinical trial.

MSP-1014, Mindset’s first lead clinical candidate, is a differentiated next-generation psilocybin-based compound in the company’s Family 1 of novel psychedelics.

READ: Maxim Group initiates coverage of Mindset Pharma with a ‘Buy’ rating and price target of US$1

Evidence suggests MSP-1014 could be more effective and safer than generic psilocybin, particularly in the treatment of neuropsychiatric conditions, according to Mindset.

Joseph Araujo, Mindset’s chief scientific officer, detailed the company’s research comparing the compound to psilocybin.

Araujo said that one critical pre-clinical study used to assess MSP-1014’s potential superior efficacy compared to psilocybin was 5-HT2A receptor activity, a serotonin subtype receptor understood to be highly correlated with a psychedelic experience.

Mindset compared MSP-1014 to psilocybin using the mouse head twitch response (HTR) assay and saw an increased number of HTRs, indicated by sequences of rapid head shakes or twitches, following three mg/kg doses of MSP-1014 compared to psilocybin.

“With equimolar doses of psilocybin and MSP-1014, MSP-1014 more than doubled HTRs in mice. When compared to psilocybin, locomotor activity was not reduced with increased doses of MSP-1014 in mice,” Araujo explained in a statement.

“These findings were confirmed in rats, in which MSP-1014 showed wet dog shakes and back muscle contractions (WDS/BMC) equal to or greater than psilocybin. Additionally, increasing doses of MSP-1014 did not result in body temperature reduction, which is seen when administering increasing doses of psilocybin.”

Mindset CEO James Lanthier told investors that the company believes MSP-1014 has the potential to be a safer and more scalable treatment option.

“MSP-1014 is just the beginning for Mindset. Mindset has developed and continues to grow a broad and diverse pipeline of improved and differentiated second and third generation psychedelic medicines with the goal of creating improved psychedelic therapeutics.”

Based in Toronto, Mindset is advancing its own proprietary therapeutics identified across its four novel families of psychedelic-inspired compounds.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Story by ProactiveInvestors